Most Recent Articles by Sony Salzman
Two late-stage orphan drugs are upping the ante with their promise to cure disease.
Two touted products in the pipeline reflect three of medical marketing's most profound modern-era challenges.
With pharma facing ongoing scrutiny of its pricing practices, medical marketers are increasingly asked to demonstrate the superior value of new therapies. High-profile candidates in immunology, pain management, and melanoma challenge marketers well in advance of launch.
The most promising products in pharma's pipeline will compete in a landscape that increasingly rewards big risks and places an emphasis on novel mechanisms. That comes with a catch.